ArticleBMC cancer2020

A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected biliary tract cancer in a multi-institutional trial (Tokyo Study Group for Biliary Cancer: TOSBIC01).

Osamu Itano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.